Collagen News and Research

Latest Collagen News and Research

Researchers show how ingesting too much silver can cause argyria

Researchers from Brown University have shown for the first time how ingesting too much silver can cause argyria, a rare condition in which patients' skin turns a striking shade of grayish blue.

31 Oct 2012

IPSCs may be a viable source of patient-specific articular cartilage tissue

A team of Duke Medicine researchers has engineered cartilage from induced pluripotent stem cells that were successfully grown and sorted for use in tissue repair and studies into cartilage injury and osteoarthritis.

30 Oct 2012

Nicotine exposure causes asthma in smoker's grandchildren

The dangers of smoking on smokers and their children are widely known but new research published in BioMed Central's open access journal BMC Medicine demonstrates that nicotine exposure also causes asthma in the smoker's grandchildren.

30 Oct 2012

Obese patients more likely to have complications after total knee replacement surgery

Obese patients have a greater risk of complications following total knee replacement surgery, including post-surgical infections, according to a new literature review recently published in the Journal of Bone and Joint Surgery (JBJS).

25 Oct 2012

Breast cancer spread dependent on both environment and genetic changes

A new study from Johns Hopkins researchers suggests that the lethal spread of breast cancer is as dependent on a tumor’s protein-rich environment as on genetic changes inside tumor cells.

23 Oct 2012

Sterile acellular matrices 'reliable in expander-based breast reconstruction'

Sterile human acellular dermal matrix offers reliable matrix incorporation and a low complication rate for expander-based breast reconstruction, the results of a US study indicate, which also suggest that sterilization does not affect incorporation success.

15 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Geographic information system software offers new way to study human remains

A common type of geographic mapping software offers a new way to study human remains. In a recent issue of the American Journal of Physical Anthropology, researchers describe how they used commercially available mapping software to identify features inside a human foot bone - a new way to study human skeletal variation.

26 Sep 2012

STAAR Surgical to participate in 88th Congress of the Society of Spanish Ophthalmologists

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it will be participating in the 88th Congress of the Society of Spanish Ophthalmologists being held in Barcelona from September 26 to 29.

26 Sep 2012

New computer program predicts most stable structures of nanometer-sized collagen

The human body is proficient at making collagen. And human laboratories are getting better at it all the time. In a development that could lead to better drug design and new treatments for disease, Rice University researchers have made a major step toward synthesizing custom collagen. Rice scientists who have learned how to make collagen - the fibrous protein that binds cells together into organs and tissues - are now digging into its molecular structure to see how it forms and interacts with biological systems.

26 Sep 2012

Alendronate decreases BMD loss in prostate cancer

Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.

19 Sep 2012

U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

15 Sep 2012

MicroRNA-145 gene therapy can drastically reduce severity and progression of atherosclerosis

Researchers at St. Michael's Hospital are one step closer to understanding why plaque bursts in coronary arteries and causes heart attacks.

11 Sep 2012

Morphological changes occur rapidly in response to cardiac injury

Cardiac injury leads to significant structural changes in the heart, including enlargement, excess formation of fibrous growth tissue, and abnormalities of the coronary vasculature. While associated factors have been targeted for therapeutic intervention, the results have been conflicting. Most studies have investigated these changes after six days of injury. However, advanced stages of remodeling have already begun by day seven following injury.

4 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Johns Hopkins team creates synthetic protein that can help locate tumors

Johns Hopkins researchers have created a synthetic protein that, when activated by ultraviolet light, can guide doctors to places within the body where cancer, arthritis and other serious medical disorders can be detected.

30 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Implanted cells' therapeutic properties depend on their shape

Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others.

16 Aug 2012